Solitary Fibrous Tumors
Welcome,         Profile    Billing    Logout  
 23 Companies   24 Products   24 Products   4 Mechanisms of Action   0 Trials   65 News 


12»
  • ||||||||||  Istodax (romidepsin) / Astellas, BMS
    Trial completion, Trial initiation date, Trial primary completion date, Metastases:  Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma (clinicaltrials.gov) -  Jun 14, 2017   
    P2,  N=40, Completed, 
    Recruiting --> Completed Active, not recruiting --> Completed | Initiation date: Jan 2004 --> Jan 2005 | Trial primary completion date: Jul 2013 --> Oct 2008
  • ||||||||||  imatinib / Generic mfg.
    Enrollment change:  Imatinib Mesylate in Treating Patients With Recurrent Meningioma (clinicaltrials.gov) -  May 15, 2017   
    P2,  N=23, Completed, 
    Active, not recruiting --> Completed | Initiation date: Jan 2004 --> Jan 2005 | Trial primary completion date: Jul 2013 --> Oct 2008 N=60 --> 23
  • ||||||||||  dasatinib / Generic mfg.
    Trial primary completion date, Metastases:  Trial of Dasatinib in Advanced Sarcomas (clinicaltrials.gov) -  Oct 13, 2016   
    P2,  N=386, Active, not recruiting, 
    N=30 --> 0 | Suspended --> Withdrawn | Trial primary completion date: Dec 2018 --> Mar 2017 Trial primary completion date: Jun 2015 --> Dec 2016
  • ||||||||||  Trial completion, Enrollment change, Trial primary completion date:  Study of Tissue Samples From Patients With Glioma or Other Brain Tumors (clinicaltrials.gov) -  Nov 24, 2015   
    P=N/A,  N=180, Completed, 
    Active, not recruiting --> Completed Recruiting --> Completed | N=150 --> 180 | Trial primary completion date: Dec 2008 --> Jul 2009
  • ||||||||||  RG4733 / Roche
    Trial completion, Enrollment change, Trial primary completion date, Combination therapy:  RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma (clinicaltrials.gov) -  Sep 29, 2015   
    P1,  N=22, Completed, 
    Recruiting --> Completed | N=150 --> 180 | Trial primary completion date: Dec 2008 --> Jul 2009 Active, not recruiting --> Completed | N=34 --> 22 | Trial primary completion date: May 2017 --> Jun 2013
  • ||||||||||  Trial primary completion date:  Yoga Therapy in Treating Patients With Malignant Brain Tumors (clinicaltrials.gov) -  Aug 13, 2015   
    P=N/A,  N=9, Terminated, 
    Active, not recruiting --> Completed | N=34 --> 22 | Trial primary completion date: May 2017 --> Jun 2013 Trial primary completion date: Dec 2013 --> Sep 2012
  • ||||||||||  dasatinib / Generic mfg.
    Enrollment change, Trial primary completion date, Metastases:  Trial of Dasatinib in Advanced Sarcomas (clinicaltrials.gov) -  Dec 19, 2014   
    P2,  N=386, Active, not recruiting, 
    Recruiting --> Suspended N=502 --> 386 | Trial primary completion date: Dec 2014 --> Jun 2015
  • ||||||||||  sunitinib / Generic mfg.
    Trial completion, Trial primary completion date:  Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma (clinicaltrials.gov) -  Oct 30, 2014   
    P2,  N=50, Completed, 
    N=502 --> 386 | Trial primary completion date: Dec 2014 --> Jun 2015 Active, not recruiting --> Completed | Trial primary completion date: Oct 2015 --> Oct 2014
  • ||||||||||  vatalanib (PTK787) / Novartis, Bayer
    Trial completion, Trial primary completion date:  Vatalanib in Treating Patients With Recurrent or Progressive Meningioma (clinicaltrials.gov) -  Oct 27, 2014   
    P2,  N=25, Completed, 
    Active, not recruiting --> Completed | Trial primary completion date: Oct 2015 --> Oct 2014 Active, not recruiting --> Completed | Trial primary completion date: Apr 2014 --> Nov 2010
  • ||||||||||  dasatinib / Generic mfg.
    Trial primary completion date, Metastases:  Trial of Dasatinib in Advanced Sarcomas (clinicaltrials.gov) -  Jun 19, 2014   
    P2,  N=502, Active, not recruiting, 
    Trial primary completion date: Oct 2014 --> Oct 2015 Trial primary completion date: Dec 2013 --> Dec 2014
  • ||||||||||  thalidomide / Generic mfg., docetaxel / Generic mfg.
    Trial completion, Metastases:  Thalidomide and Docetaxel in Treating Patients With Advanced Cancer (clinicaltrials.gov) -  Feb 22, 2014   
    P1,  N=26, Completed, 
    Suspended --> Completed Active, not recruiting --> Completed
  • ||||||||||  Jingzhuda (entinostat) / EOC Pharma, EddingPharm
    Trial completion, Epigenetic controller, Metastases:  MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma (clinicaltrials.gov) -  Feb 19, 2014   
    P1,  N=75, Completed, 
    Active, not recruiting --> Completed Active, not recruiting --> Completed
  • ||||||||||  Trial completion:  Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer (clinicaltrials.gov) -  Apr 29, 2013   
    P1,  N=60, Completed, 
    Suspended --> Terminated; Results of step1: none of the experimental arms fulfills expectations and the study will not continue as a phase III. Active, not recruiting --> Completed
  • ||||||||||  ifosfamide / Generic mfg.
    Trial termination:  S9624 Ifosfamide in Treating Patients With Meningeal Tumors (clinicaltrials.gov) -  Nov 18, 2012   
    P2,  N=7, Terminated, 
    Completed --> Terminated; Administratively complete. Withdrawn --> Terminated; lack of accrual